MedTrace Logo

Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members

NCT04813497 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2022-06-01

No results posted yet for this study

Summary

Grand Hôpital de Charleroi (GHdC) had to organize the vaccination of its staff in December 2021 against SARS-CoV-2.On the sidelines of this vaccination campaign, the management committee agreed to document the knowledge of the SARS-CoV-2 serology of all the staff of the establishment before this vaccination campaign, as well as a few weeks after vaccination.

In November 2021, the Belgian government decided to offer a third dose of vaccine against SARS-CoV-2 virus. The GHdC managment committee has agreed to continue monitoring SARS-CoV-2 serology for members who receive their third dose of vaccine.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

Serology to determine SARS-CoV-2 infection

Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood

Sponsors & Collaborators

  • Grand Hôpital de Charleroi

    lead OTHER

Principal Investigators

  • Natahie de Visscher, MD · Grand Hôpital de Charleroi

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-05
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04813497 on ClinicalTrials.gov